IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

Sandoz Gains Biosimilar Approval

9:58 AM MDT | July 10, 2009

Sandoz (Holzkirchen, Germany), a division of Novartis, says it has received marketing authorization for the first ever biosimilar to be sold in Japan. Approval of the product, recombinant human growth hormone somatropin, paves the way for greater market access for high-quality biopharmaceuticals in Japan, Sandoz says. Japan is the second-largest pharmaceuticals market after the U.S. Biosimilars are approved versions of innovator biopharmaceutical products, following patent expiry. The Sandoz product is approved for the treatment of growth hormone deficiency in...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa